Airway Medix (FRA:D1C) 3-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:D1C Airway Medix SA FRA:D1C
17 GF Score
Price €0.05
! 9 Warning Signs
View Full Analysis

What is Airway Medix 3-Year EBITDA Growth Rate?

Airway Medix FRA:D1C +0.88% 17 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates FRA:D1C with a GF Score™ of 17/100. The stock has 9 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Airway Medix ranks worse than 145348.69% on this metric.

Airway Medix's EBITDA per Share for the three months ended in Mar. 2026 was €-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Airway Medix was 27.40% per year. The lowest was -224.70% per year. And the median was -2.60% per year.

Airway Medix  (FRA:D1C) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Airway Medix 3-Year EBITDA Growth Rate Related Terms

FRA:D1C vs ISRG, BDX, RMD: 3-Year EBITDA Growth Rate Comparison

For the Medical Instruments & Supplies subindustry, Airway Medix's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Airway Medix 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Airway Medix's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Airway Medix's 3-Year EBITDA Growth Rate falls into.


FRA:D1C
17GF Score
Airway Medix SA FRA:D1C
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Airway Medix 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Airway Medix (FRA:D1C) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Airway Medix and its competitors. According to the industry distribution chart, Airway Medix ranks #999999 out of 688 companies in the Medical Devices & Instruments industry.
Is Airway Medix's 3-Year EBITDA Growth Rate too high?
Airway Medix's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Airway Medix ranks #999999 out of 688 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Airway Medix has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Airway Medix's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Airway Medix ranks #999999 out of 688 companies for 3-Year EBITDA Growth Rate. This places Airway Medix in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Airway Medix and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Airway Medix's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Airway Medix stock overvalued right now?
Airway Medix (FRA:D1C) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Airway Medix's overall GF Score™ is 17/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Airway Medix (FRA:D1C), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Airway Medix Business Description

Other Exchanges AWM:Poland
Address ul. Szara 10, Warszawa, POL, 00-420
Airway Medix SA focuses on research, development, and commercialization of devices for single use in mechanically ventilated patients at Intensive Care Units as well as in patients with life-threatening and anaesthesiologic wards. The company's products include the Closed Suction System, the Oral Care System, and the Cuff Pressure Regulator.
17GF Score

Get the complete analysis for FRA:D1C

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price